This issue new drugs provides an insight into the latest developments in drug discovery tlU"ough brief synopses of recent presentations and publications.
The widely used nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the cyclooxygenase (COX) which converts arachidonic acid into prostaglandins (PGs). COX exists in at least two isoforms.
COX-1 (constitutive isoform) is present constitutively under physiological condition. COX-2 (inducible isoform) is induced in various cell types by mitogens and cytokines including endotoxin. The marketed NSAIDs are differential effects on COX-1 and COX-2. PGs produced by COX-1 have important role in normal platelet, gastric and renal function . As a consequence, inhibition of COX-1 results in unwanted side effects. The developing selective COX-2 inhibitors may offer an advantage over the existing non-selective NSAIDs by reducing the associated renal and gastric toxicity.
Some of these new drugs are: 1. A novel series of 1,2-diarylcyclobutenes has evaluated as potential selective COX-2 inhibitors. 4,4-d i me -thy l -2 -phenyl -3 -[ 4 -(methylsulphonyl)phenyl]cyclobuten one (figure 1) was shown to be pru1icularly selective for COX-2 and orally active in the rat paw edema model (EDso = 2.4 mg/kg). (Friesen and coworkers. Bioorg Med Chem Lett 1996; 6: 2677 -2682 .
2. The agents based on the synthesis and evaluation of series of 1,5-diarylpyrazones containing either a sulphone or sulphonamide moiety as COX-1 and COX-2 inhibitors have been described . The series of benzothiopyrano-pyrazoles, exemplified by figure 2, were found to be both selective COX-2 inhibitors in vitro and antiinflammatory agents in vitro in the air-pouch model ·of inflammation.
(Bertenshaw and coworkers. Bioorg Med Chem Lett 1996; 6: 2827-2830).
3. DuPont Merck (Wilmington, DE, USA) has described the new class of COX-2 inhibitors, the terphe-nyls, which they discovered while seeking to improve the in vitro selectivity of their selective COX-2 inhibitor, diarylthio-phen (figure 3 DuP697). The terphenyl compound (figure 4) was identified as a potential lead compound having good COX-2 selectivity and a better pharmacokinetic profile than DuP697. 6. The agents based on the synthesis and evaluation of 1,2-diaryl-imidazoles as COX-2 inhibitors have been described. These compounds were also found to be potent and highly selective inhibitors of the human COX-2 enzyme. Several of these com-pounds, exemplified by figure 7, were found to exhibit excellent inhibition in the adjuvant-induced ai1hritis model (EDso = 0.02 mg/kg figure 7
